{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:17:52Z","timestamp":1779376672743,"version":"3.53.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11060-023-04551-9","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:02:56Z","timestamp":1708354976000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab"],"prefix":"10.1007","volume":"167","author":[{"given":"Pushan","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin D.","family":"Alfaro-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Afshar-Khargan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kamiya-Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin K.","family":"Majd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"4551_CR1","doi-asserted-by":"publisher","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987\u201396. doi: https:\/\/doi.org\/10.1056\/NEJMoa043330. PMID: 15758009.","DOI":"10.1056\/NEJMoa043330"},{"issue":"3","key":"4551_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","volume":"89","author":"LC Marras","year":"2000","unstructured":"Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89(3):640\u2013646","journal-title":"Cancer"},{"key":"4551_CR3","doi-asserted-by":"publisher","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B \u2026 van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The Lancet. Oncology,\u00a015(9), 943\u2013953. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","DOI":"10.1016\/S1470-2045(14)70314-6"},{"issue":"4","key":"4551_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","volume":"28","author":"OL Chinot","year":"2011","unstructured":"Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28(4):334\u2013340. https:\/\/doi.org\/10.1007\/s12325-011-0007-3","journal-title":"Adv Ther"},{"key":"4551_CR5","doi-asserted-by":"publisher","unstructured":"Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, Marosi C. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007 Apr;9(2):89\u201395. doi: https:\/\/doi.org\/10.1215\/15228517-2006-035. Epub 2007 Feb 27. PMID: 17327573; PMCID: PMC1871666.","DOI":"10.1215\/15228517-2006-035"},{"key":"4551_CR6","doi-asserted-by":"publisher","unstructured":"Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004 Apr 15;100(8):1717-23. doi: https:\/\/doi.org\/10.1002\/cncr.20150. PMID: 15073862","DOI":"10.1002\/cncr.20150"},{"key":"4551_CR7","doi-asserted-by":"publisher","unstructured":"Mir Seyed Nazari P, Riedl J, Preusser M, Posch F, Thaler J, Marosi C, Birner P, Ricken G, Hainfellner JA, Pabinger I, Ay C. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thromb Haemost. 2018 Jun;16(6):1121\u20131127. doi: https:\/\/doi.org\/10.1111\/jth.14129. Epub 2018 May 20. PMID: 29676036; PMCID: PMC6099350.","DOI":"10.1111\/jth.14129"},{"key":"4551_CR8","doi-asserted-by":"publisher","unstructured":"Nabi S, Kahlon P, Bozorgnia F, Arshad A, Mikkelsen T, Donthireddy V. Predictors of Venous Thromboembolism in Patients with Glioblastoma. Pathol Oncol Res. 2016 Apr;22(2):311-6. doi: https:\/\/doi.org\/10.1007\/s12253-015-0008-7. Epub 2015 Nov 7. PMID: 26547860","DOI":"10.1007\/s12253-015-0008-7"},{"key":"4551_CR9","doi-asserted-by":"publisher","unstructured":"Thaler J, Ay C, Kaider A, Reitter EM, Haselb\u00f6ck J, Mannhalter C, Zielinski C, Marosi C, Pabinger I. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2014 Dec;16(12):1645\u201351. doi: https:\/\/doi.org\/10.1093\/neuonc\/nou106. Epub 2014 Jul 1. PMID: 24987133; PMCID: PMC4232082.","DOI":"10.1093\/neuonc\/nou106"},{"key":"4551_CR10","doi-asserted-by":"publisher","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: https:\/\/doi.org\/10.1200\/JCO.2008.19.8721. Epub 2009 Aug 31. PMID: 19720927","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"4551_CR11","doi-asserted-by":"publisher","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709-22. doi: https:\/\/doi.org\/10.1056\/NEJMoa1308345. PMID: 24552318","DOI":"10.1056\/NEJMoa1308345"},{"key":"4551_CR12","doi-asserted-by":"publisher","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: https:\/\/doi.org\/10.1056\/NEJMoa1707358. PMID: 29141164","DOI":"10.1056\/NEJMoa1707358"},{"key":"4551_CR13","doi-asserted-by":"publisher","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014 Aug;15(9):943-53. doi: https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6. Epub 2014 Jul 15. PMID: 25035291","DOI":"10.1016\/S1470-2045(14)70314-6"},{"key":"4551_CR14","doi-asserted-by":"publisher","unstructured":"Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011 Nov;105(2):281\u20139. doi: https:\/\/doi.org\/10.1007\/s11060-011-0579-4. Epub 2011 Apr 27. PMID: 21603965; PMCID: PMC3168718.","DOI":"10.1007\/s11060-011-0579-4"},{"key":"4551_CR15","doi-asserted-by":"publisher","unstructured":"Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost. 2016 Sep;14(9):1736-40. doi: https:\/\/doi.org\/10.1111\/jth.13387. Epub 2016 Jul 29. PMID: 27306689","DOI":"10.1111\/jth.13387"},{"issue":"6","key":"4551_CR16","doi-asserted-by":"publisher","first-page":"e01638","DOI":"10.1002\/brb3.1638","volume":"10","author":"A Porfidia","year":"2020","unstructured":"Porfidia A, Giordano M, Sturiale CL et al (2020) Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis. Brain Behav 10(6):e01638. https:\/\/doi.org\/10.1002\/brb3.1638","journal-title":"Brain Behav"},{"key":"4551_CR17","doi-asserted-by":"publisher","unstructured":"Lee I, Adimadhyam S, Nutescu EA, Zhou J, Asfaw AA, Sweiss KI, Patel PR, Calip GS. Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. Pharmacotherapy. 2019 Sep;39(9):921\u2013928. doi: https:\/\/doi.org\/10.1002\/phar.2310. Epub 2019 Aug 6. PMID: 31332810; PMCID: PMC7395667.","DOI":"10.1002\/phar.2310"},{"key":"4551_CR18","doi-asserted-by":"publisher","unstructured":"Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci. 2020 Apr;74:36-40. doi: https:\/\/doi.org\/10.1016\/j.jocn.2020.01.066. Epub 2020 Jan 23. PMID: 31982279","DOI":"10.1016\/j.jocn.2020.01.066"},{"key":"4551_CR19","doi-asserted-by":"publisher","unstructured":"Lin X, Daras M, Pentsova E, Nolan CP, Gavrilovic IT, DeAngelis LM, Kaley TJ. Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. Neurooncol Pract. 2017 Mar;4(1):24\u201328. doi: https:\/\/doi.org\/10.1093\/nop\/npw008. Epub 2016 Dec 9. PMID: 31044081; PMCID: PMC6479824.","DOI":"10.1093\/nop\/npw008"},{"key":"4551_CR20","doi-asserted-by":"publisher","unstructured":"Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017 Jun 22;129(25):3379-3385. doi: https:\/\/doi.org\/10.1182\/blood-2017-02-767285. Epub 2017 May 3. PMID: 28468796","DOI":"10.1182\/blood-2017-02-767285"},{"key":"4551_CR21","doi-asserted-by":"publisher","unstructured":"Lim G, Ho C, Roldan Urgoti G, Leugner D, Easaw J. Risk of Venous Thromboembolism in Glioblastoma Patients. Cureus. 2018 May 23;10(5):e2678 https:\/\/doi.org\/10.7759\/cureus.2678 PMID: 30050733; PMCID: PMC6059517","DOI":"10.7759\/cureus.2678"},{"issue":"12","key":"4551_CR22","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1161\/STROKEAHA.121.035233","volume":"52","author":"A Alkhachroum","year":"2021","unstructured":"Alkhachroum A, Bustillo AJ, Asdaghi N, Marulanda-Londono E, Gutierrez CM, Samano D, Sobczak E, Foster D, Kottapally M, Merenda A, Koch S, Romano JG, O\u2019Phelan K, Claassen J, Sacco RL, Rundek T (2021) Withdrawal of Life-Sustaining Treatment Mediates Mortality in Patients With Intracerebral Hemorrhage With Impaired Consciousness. Stroke 52(12):3891\u20133898. https:\/\/doi.org\/10.1161\/STROKEAHA.121.035233","journal-title":"Stroke"},{"issue":"2","key":"4551_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/nop\/npv028","volume":"3","author":"MN Khoury","year":"2016","unstructured":"Khoury MN, Missios S, Edwin N, Sakruti S, Barnett G, Stevens G, Peereboom DM, Khorana AA, Ahluwalia MS (2016) Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. Neuro-oncology practice 3(2):87\u201396. https:\/\/doi.org\/10.1093\/nop\/npv028","journal-title":"Neuro-oncology practice"},{"key":"4551_CR24","doi-asserted-by":"publisher","unstructured":"Tawil, N., Bassawon, R., Meehan, B., Nehme, A., Montermini, L., Gayden, T., De Jay, N., Spinelli, C., Chennakrishnaiah, S., Choi, D., Adnani, L., Zeinieh, M., Jabado, N., Kleinman, C. L., Witcher, M., Riazalhosseini, Y., Key, N. S., Schiff, D., Grover, S. P., Mackman, N., \u2026 Rak, J. (2021). Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.\u00a0Blood advances,\u00a05(6), 1682\u20131694. https:\/\/doi.org\/10.1182\/bloodadvances.2020002998","DOI":"10.1182\/bloodadvances.2020002998"},{"key":"4551_CR25","doi-asserted-by":"publisher","unstructured":"RAK J, Magnusa N, Garniera D, Meehana B, McGrawa S, Leea TH, Caronb M, Bourqueb G, Milsomc C, Jabadoa N, Traslera J. Procoagulant tissue factor expression is linked to distinct subtypes in glioblastoma and plays a role in tumor dormancy. Neuro Oncol. 2014 Jul;16(Suppl 3):iii1\u2013iii22. doi: https:\/\/doi.org\/10.1093\/neuonc\/nou206.77. PMCID: PMC4144547.","DOI":"10.1093\/neuonc\/nou206.77"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04551-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04551-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04551-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T12:10:02Z","timestamp":1711627802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04551-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["4551"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04551-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"2 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by MD Anderson Cancer Center\u2019s institutional review board.This study was approved and met criteria for exemption from IRB review by University of Texas at Austin\u2019s Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}